PCM
AZN icon

PenderFund Capital Management’s AstraZeneca AZN Stock Holding History

PenderFund Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,665
Closed -$323K – 235
2026
Q1 		$323K Hold
1,665
– – 0.05% 110
2025
Q4 		$306K Hold
1,665
– – 0.05% 93
2025
Q3 		$255K Buy
+1,665
New +$252K 0.04% 92

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PenderFund Capital Management's AZN Position: Q2 2026 in Review

PenderFund Capital Management sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 1,665 shares — an estimated $323K sold.

PenderFund Capital Management first reported a position in AZN in Q3 2025 and held it in 3 quarters. The position peaked at $323K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • PenderFund Capital Management reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
  • PenderFund Capital Management sold 1,665 AstraZeneca shares in Q2 2026, an estimated $323K.
  • PenderFund Capital Management first reported a position in AstraZeneca in Q3 2025 and held it in 3 quarters.
  • PenderFund Capital Management's AstraZeneca position peaked at $323K in Q1 2026.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on PenderFund Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.